Detalhe da pesquisa
1.
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Haematologica
; 104(4): 797-804, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30467205
2.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Lancet Oncol
; 17(2): 200-211, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655421
3.
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Haematologica
; 101(12): 1573-1580, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27198718
4.
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Haematologica
; 104(5): e208-e210, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514799
5.
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
Nat Cancer
; 3(2): 251-261, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35221333
6.
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Br J Haematol
; 144(1): 78-85, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19016731
7.
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression.
Br J Haematol
; 159(5): 608-12, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23043283
8.
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
Nat Cancer
; 3(5): 649, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35449310
9.
Strategies in the management of alemtuzumab-related side effects.
Semin Oncol
; 33(2 Suppl 5): S29-35, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16720201
10.
Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia.
Med Oncol
; 23(1): 137-9, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16645240
11.
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region.
Leuk Lymphoma
; 55(8): 1774-80, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24237446
12.
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Curr Hematol Malig Rep
; 4(1): 47-53, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20425438
13.
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
Br J Haematol
; 135(4): 475-85, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16995884